focus -WSS

focus

author：hotspot 2025-09-27 16:50:04 - browse：76961

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Humana, CVS hope to turn members into patients at clinics

WSS

For BCIs, commercial hurdles may be bigger than scientific ones

Ozempic has benefits for kidney disease as well as diabetes

The drug industry sees a key ally in the Senate prevail

Biden calls for immediate release of Niger's president amid apparent coup

White House drug shortage group privately met with industry

'Ancient DNA,' 23andMe reveal African American ancestries

focus

focus

hotspot

Medical records are filled with copy

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Drug repurposing or repositioning? The language matters

Biden calls for immediate release of Niger's president amid apparent coup

Moonlake's readout produced a cash windfall. Risks remain

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

OTC birth control: A brief history of over the counter pill design

Tori Bowie and the unacceptable rates of Black maternal death

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

explore

White House drug shortage group privately met with industry

Why Talkspace is targeting Medicare, a tricky market

TytoCare raises $49 million to build out AI

Readout Newsletter: BridgeBio, Akero, and human embryo models

IVF doctors demand details after CooperSurgical lawsuit

The public health thinking behind the CDC’s new Covid guidance

Wikipedia

focus

hotspot

leisure time